Arcutis Biotherapeutics, Inc.
ARQT
$22.91
$0.673.01%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 127.50M | 99.22M | 81.50M | 63.85M | 69.36M |
| Total Other Revenue | 2.00M | -- | -- | 2.00M | 2.00M |
| Total Revenue | 129.50M | 99.22M | 81.50M | 65.85M | 71.36M |
| Cost of Revenue | 11.69M | 8.69M | 7.49M | 8.83M | 6.91M |
| Gross Profit | 117.82M | 90.53M | 74.01M | 57.02M | 64.46M |
| SG&A Expenses | 78.98M | 62.40M | 69.17M | 64.00M | 57.61M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 111.12M | 90.69M | 96.12M | 90.38M | 78.99M |
| Operating Income | 18.39M | 8.53M | -14.61M | -24.53M | -7.63M |
| Income Before Tax | 17.87M | 7.49M | -15.54M | -24.78M | -10.47M |
| Income Tax Expenses | 470.00K | 80.00K | 342.00K | 279.00K | 323.00K |
| Earnings from Continuing Operations | 17.40M | 7.41M | -15.89M | -25.06M | -10.79M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 17.40M | 7.41M | -15.89M | -25.06M | -10.79M |
| EBIT | 18.39M | 8.53M | -14.61M | -24.53M | -7.63M |
| EBITDA | 18.95M | 9.09M | -14.20M | -21.40M | -7.32M |
| EPS Basic | 0.14 | 0.06 | -0.13 | -0.20 | -0.09 |
| Normalized Basic EPS | 0.09 | 0.04 | -0.08 | -0.12 | -0.05 |
| EPS Diluted | 0.12 | 0.06 | -0.13 | -0.20 | -0.09 |
| Normalized Diluted EPS | 0.08 | 0.04 | -0.08 | -0.12 | -0.05 |
| Average Basic Shares Outstanding | 128.25M | 127.62M | 127.00M | 126.04M | 124.92M |
| Average Diluted Shares Outstanding | 135.64M | 132.88M | 127.00M | 126.04M | 124.92M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |